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Abstract
Background: Janus kinase-signal transducer and activator of transcription (JAK-STAT) is a family of intracellular, nonreceptor tyrosine kinases that 
transduce cytokine-mediated signals. In the beginning of 20th century, it was named “just another kinase” but by some reasons ultimately it was published 
as “Janus kinase”. The name Janus was taken from the two-faced Roman god of beginnings, endings and duality, because the Janus kinases (JAKs) possess 
two near-identical phosphate-transferring domains, one domain exhibits the kinase activity, while the other negatively regulates the kinase activity of 
the first one. The article describes JAK-STAT in many aspects such as general definition, mechanism of action, biochemical qualities and the relation to 
cancer. Eventually the article will explain the role of JAK-STAT pathway in carcinogenesis and summarize the article through future direction in clinical 
medicine and research. 
Conclusions: Understanding JAK-STAT pathway can help physicians, medical students and teachers apply this into clinical practice. By discovering more 
about the JAK-STAT pathway, many cancer diseases could be halted or treated due to their connection to cancer therapy.
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Introduction
Janus kinases (JAKs) are a family of cytoplasmic recep-
tors associated with protein tyrosine kinases required for 
cytokine signaling and signal transducer activators of tran-
scription (STAT) are transcription factors which regulate 
some genes required for cellular proliferation, differentia-
tion and survival. Aberrant activation of intracellular sig-
naling of JAK-STAT pathways resulting from mutations is 
associated with many types of cancers. Targeting intracel-
lular signaling pathways has been a productive strategy for 
drug development, with several drugs acting on signaling 
pathways already in use and more continually being de-
veloped. The STATs form dimers that translocate to the 
nucleus when phosphorylated on highly conserved tyrosine 
residues (termed pSTAT) by JAKs or other tyrosine kinases. 
The STAT dimers bind specific promoter sequences and 
modulate transcription of genes controlling cellular pro-
cesses including proliferation, differentiation and apoptosis. 
In addition to the established role of the JAK-STAT signal-
ing pathway, cytokine traditionally signals the noncoding 
ribonucleic acid (RNA) [1]. Understanding the crosstalk of 
non-coding RNA with JAK-STAT signaling in cancer is of 
critical importance and may result in better patient stratifi-
cation not only in terms of prognosis but also in the context 
of therapy.
The JAK-STAT pathway is important in cytokine-medi-
ated immune responses. Research in the JAK-STAT field has 
elucidated its roles in various cellular processes such as pro-
liferation, apoptosis and migration, and has found frequent 
dysregulation of the JAK-STAT pathway in diverse types of 
cancer. A similar interaction occurs in human cells, where 
unphosphorylated STAT5A interacts with heterochromatin 
protein 1α (HP) and acts as a tumor suppressor. Nuclear 
JAK2 however, functions as a histone tyrosine kinase, dis-
placing HP1α from chromatin. These data have important 
implications for human cancer: They suggest new drug 
therapies, which could target the not canonical functions of 
JAK and STAT [2, 3].
The (JAK-STAT) pathway plays a major role in transfer-
ring of signals from cell-membrane receptors to the nucleus. 
The JAKs are now recognized as an integral component of 
the cytokine receptor subunits, and enzyme activation, as 
the initiating step in a signaling cascade required for em-
bryonic development, tissue growth, haemopoietic develop-
ment and differentiation, innate and adaptive immunity and 
the inflammatory response. There is a reciprocal interaction 
between external actions and internal reactions that enables 
a cell to live. Each receptor like a sentinel senses stimulus 
and starts to transfer corps of signals to the 3d castle of the 
nucleus in order to provoke vital responses. The result of 
this process may be proliferation, differentiation (polariza-
tion), activation/inhibition and survival/apoptosis [4]. The 
role of JAK-STAT signalling in the pathogenesis, progno-
sis and treatment of solid tumours is divided into many 
aspects.  The JAK-STAT pathway regulates embryonic de-
velopment and is involved in the control of processes such 
as stem cell maintenance, haematopoiesis and the inflam-
matory response.  The pathway transduces signals from cy-
tokines, interleukins and growth factors that act through a 
number of transmembrane receptor families. Type I recep-
tors include the erythropoietin receptor and the granulo-
cyte colony-stimulating factor receptor. The granulocyte-
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macrophage colony-stimulating factor receptor is a type IIa 
receptor and the type IIb subfamily includes the receptors 
for interleukin-6 and leukaemia inhibitory factor. The intra-
cellular tails of these receptors are constitutively associated 
with inactive kinases named Janus kinases. While cellular 
overexpression studies suggested JAKs could signal promis-
cuously downstream of many cytokine receptors, it is evi-
dent from genetic deletion studies that cytokine receptors 
have clear preferences for the JAK family members which 
they utilize as signaling effectors. In light of this fact, here 
we have focused our attention on the genetic deletion stu-
dies that have illuminated which JAKs couple with which 
cytokine receptors. The first insights into the specificity of 
JAKs within each signaling pathway arose from early cell-
based genetic screens to identify components of the IFNα/β 
and IFNγ signaling pathways [5, 6, 7].
The JAK-STAT pathway has been known for many years 
as a key pathway for the vitality functions of many cells in 
our body both in the blood system and even in the respirato-
ry system or reproductive system. The role of JAK-STAT has 
been increasingly growing over the past year while more re-
searches were published. In this article are considered many 
important studies that were conducted in the recent years. 
We will try to explain the mechanism of this apparatus, and 
what happens if the apparatus fails and leads to dysregula-
tion of some cells. It is exclusively important to explain what 
medicines are found today on the pharmaceutical markets, 
their significance in different types of cancer and their func-
tion on the JAK-STAT pathway [8].
The role of the JAK-STAT pathway in carcinogenesis
The JAK-STAT pathway plays a major role in transfer-
ring of signals from cell-membrane receptors to the nucleus. 
Cancer involves abnormal and uncontrollable cell growth in 
a part of the body. Therefore, since JAK-STAT signaling can 
allow the transcription of genes involved in cell division, 
one potential effect of excessive JAK-STAT signaling is can-
cer formation. High levels of STAT activation have been as-
sociated with cancer; in particular, high amounts of STAT3 
and STAT5 activation are mostly linked to more dangerous 
tumors [9, 10]. For example, too much STAT3 activity has 
been associated with increasing the likelihood of melano-
ma (skin cancer) returning after treatment and abnormally 
high levels of STAT5 activity have been linked to a greater 
probability of patient’s death from prostate cancer [11, 12]. 
Altered JAK-STAT signaling can also be involved in de-
veloping breast cancer. JAK-STAT signaling in mammary 
glands (located within breasts) can promote cell division 
and reduce cell apoptosis during pregnancy and puberty, 
and therefore if excessively activated, cancer can form. High 
STAT3 activity plays a major role in this process, as it can 
allow the transcription of genes such as B-cell lymphoma 
2 and c-Myc Oncogene, which are involved in cell division.
Mutations in JAK2 can lead to leukemia and lymphoma 
[13]. Specifically, mutations in exons 12, 13, 14 and 15 of 
the JAK2 gene are supposed to be a risk factor in develop-
ing lymphoma or leukemia. Additionally, mutated STAT3 
and STAT5 can increase JAK-STAT signaling in natural 
killer and T cells, which promotes very high proliferation 
of these cells, and increases the likelihood for developing 
leukemia [14, 15, 16]. Also, a JAK-STAT signaling path-
way mediated by erythropoietin, which usually allows the 
development of red blood cells, may be altered in patients 
with leukemia. Early evidence that JAK-STAT signaling is 
activated in solid tumors was derived from cancer cell lines 
[16, 17]. There is now substantial data demonstrating ty-
rosine phosphorylation and nuclear localization of STATs, 
indicative of STAT activation, in tumor tissue derived from 
many patients across a range of tumor types. A relationship 
between JAK-STAT activation and prognosis has been ob-
served in many of these tumor types. In general, activation 
of STAT3 or STAT5 is associated with a worse prognosis, 
although in breast cancer and in some studies of colorec-
tal cancer and head and neck squamous cell carcinoma it 
appears to be associated with more favorable outcomes. In 
breast cancer, this relationship is consistent with the role of 
pSTAT5 in normal physiology – constitutive phosphoryla-
tion of STAT5 is a feature of normal breast epithelial cells, 
where it is thought to promote differentiation [18, 19, 20].
For other tumor types, differences in the strategies are 
used to quantify STAT phosphorylation, which vary across 
all the studies described below, may account for the appa-
rently conflicting associations between STAT phosphoryla-
tion and outcome. Interestingly, there is some evidence that 
in Myeloproliferative Neoplasms STAT3 may oppose malig-
nant proliferation, suggesting this may also occur in certain 
situations in solid tumors. Activation of STAT1, in contrast, 
is generally associated with better outcomes across all tu-
mor types (tab. 1) [21-28].
In conclusion, the table 1 shows different types of cancer 
in human body which relates to the STAT activation. By un-
derstanding the source of the problem and using immuno-
chemistry, we can pinpoint the mechanism that elicits those 
cancers. As the clinical medicine will use those methods for 
cancer detection, it will be easier to prevent, treat and halt 
many malignant diseases.
In some research papers [29, 30, 31], we found that 
STAT5A/B is an important immunohistochemical marker 
for prostate cancer as in other research studies [21, 22, 23] 
were found identical findings for the assesment of the pro-
gression of prostate cancer by simple immunoshistoche-
mistry. While understanding this phenomena, we can as-
sess this marker in specific people and direct it for patient’s 
management such as prostatectomy. In those researches was 
also found association with this STAT activation and the 
risk for developing non-small lung cancer.
In addition, the presence of pSTAT3 in immunohisto-
chemistry examination was associated with the decrease in 
overall survival in patients with prostate cancer [32]. After 
getting to know this mechanism of cancer some resear-
ches work on therapy. In 2013 a research about JAK-STAT 
blockage did not succeed in proving that Siltuximab (JAK-
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STAT inhibitor) can halt prostate disease. Another research 
in 2012, found out that interleukin-6 antibody, was able to 
halt several types of cancer such as multiple myeloma, non-
small cell lung cancer, colorectal cancer, renal cell carcino-
ma and prostate cancer [33].
Patients with oral squamous cell carcinoma pSTAT3 
positive with special immunohistochemistry detection 
which is called automated quantitative analysis, had shorter 
disease-free survival in comparison with other patients (13 
months vs 64 months) [34, 35]. But high nuclear STAT3 
was surprisingly associated with improved overall survival 
(mean 119 months vs 57.3 months) in patients with oral 
squamous cell carcinoma.
Cervical squamous cell carcinoma has similar perspec-
tive with oral squamous cell carcinoma, while using immu-
nohistochemistry for nuclear pSTAT3 associated with re-
duced overall survival (5-year survival 79.2 months vs 95.3 
months) [34, 35].
The role of JAK-STAT signaling in the pathogenesis, 
prognosis and treatment of solid tumours that was de-
scribed above on several types of cancer is supposed to be 
fascinating phenomena in biochemistry and oncology.
Finally, the prospects for treating solid tumours are 
analyzed using strategies targeting JAK-STAT signalling, 
including what can be learned from haematological ma-
lignancies and the extent to which results in solid tumours 
might be expected to differ [36, 37, 38].
Conclusions
1.  According to recent studies JAK-STAT pathway has a 
significant role in the control of immunity, cell proliferation 
and apoptosis.
2.  Many studies showed that defects which activate JAK-
STAT pathway can lead to different types of cancer. Finding 
defected components of this pathway can help to under-
stand the mechanism of tumor genesis.
3. Finding defected components of this pathway can help 
us diagnose various cancer diseases.
4.  Also, we can use these defected proteins as a target 
to inhibit the progression of the disease and produce new 
drugs.
5.  After many researches, we still must continue to learn 
more about different components of the JAK-STAT appa-
ratus. 
6.  Cancer progression might be in the future less accel-
erated after discovering more about JAK-STAT.
References
1. Thomas SJ, Snowden JA, Zeidler MP, Danson SJ. The role of JAK/
STAT signalling in the pathogenesis, prognosis and treatment of solid 
tumours. Br J Cancer. 2015;113(3):365-371.
2. Pencik J, Pham HT, Schmoellerl J, et al. JAK-STAT signaling in cancer: 
from cytokines to non-coding genome. Cytokine. 2016;87:26-36.
3. Chim CS, Fung TK, Cheung WC, et al. SOCS1 and SHP1 hypermeth-
ylation in multiple myeloma: implications for epigenetic activation of 
the Jak/STAT pathway. Blood. 2004;103(12):4630-4635.
Table 1
Types of cancers associated with the JAK-STAT pathway
Cancer type STAT activation, tissue sample Clinical implications of STAT activation
Non-small cell lung 
cancer 
STAT3 and pSTAT3 detection with immunohis-
tochemistry
Positivity for STAT3 or pSTAT3 associated with reduced overall 
survival
Prostate Nuclear STAT5A/B, immunohistochemistry on 
tissue microarrays from prostatectomy
Presence of nuclear STAT5 associated with early recurrence.
Presence of nuclear STAT5 associated with prostate cancer-specific 
death
Breast Immunohistochemistry for pSTAT3 on tissue 
microarrays
Immunohistochemistry and immunofluores-
cence for nuclear pSTAT5 on tissue microarrays
Presence of pSTAT3 associated with improved overall survival in 
patients receiving adjuvant chemotherapy (10-year survival 79% for 
pSTAT3 positive, vs 61.5% for pSTAT3 negative).
Absence of activated STAT5 associated with decreased cancer-
specific survival
Rectal/colorectal Immunohistochemistry for nuclear pSTAT3 Presence of activated STAT3 associated with better overall surviv-
al. Presence of activated STAT3 associated with worse overall survival
Oral squamous cell 
carcinoma
Immunohistochemistry for nuclear pSTAT3.
Automated quantitative analysis immunohis-
tochemistry for nuclear STAT3
Nuclear pSTAT3 associated with shorter median disease-free survival 
(13 months vs 64 months).
High nuclear STAT3 associated with improved overall survival (Mean 
119 months vs 57.3 months)
Cervical squamous cell 
carcinoma
Immunohistochemistry for nuclear pSTAT3 Nuclear pSTAT3 associated with reduced overall survival (5-year 
survival 79.2 months vs 95.3 months)
Malignant melanoma Immunohistochemistry for pSTAT1 and pSTAT3 In patients with lymph node metastases, higher rates of recurrence 
with high pSTAT3. Lower rates of recurrence with high pSTAT1 stain-
ing in lymph node and brain metastases
Renal cell carcinoma Immunohistochemistry for nuclear pSTAT3 Nuclear pSTAT3 associated with shortened cancer-specific survival 
Glioblastoma Immunohistochemistry for pSTAT3 on tissue 
microarrays
High or very high number of cells positive for pSTAT3 associated 
with reduced overall survival 
L. Shoev et al. Moldovan Medical Journal. September 2019;62(3):48-51ReVIeW ARTIcLe
4. Nakahara H, Nishimoto N. Anti-interleukin-6 receptor antibody 
therapy in rheumatic diseases. Endocr Metab Immune Disord Drug 
Targets. 2006;6(4):373-381.
5. Dutta P, Li WX. Role of the JAK-STAT signalling pathway in cancer. 
In: Wiley Online library. Chichester: John Wiley & Sons; 2013.
6. Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prog-
nosis in primary myelofibrosis. Leukemia. 2013;27(9):1861-1869.
7. Lasho TL, Jimma T, Finke CM, et al. SRSF2 mutations in primary 
myelofibrosis : significant clustering with IDH mutations and inde-
pendent association with inferior overall and leukemia-free survival. 
Blood. 2012;120(20):4168-4171. 
8. Kanno Y, Vahedi G, Hirahara K, et al. Transcriptional and epigenetic 
control of T helper cell specification: molecular mechanisms underly-
ing commitment and plasticity. Annu Rev Immunol. 2012;30:707-731. 
9. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: 
a leading role for STAT3. Nat Rev Cancer. 2009;9(11):798-809.
10. Ho K, Valdez F, Garcia R, Tirado CA. JAK2 Translocations in hema-
tological malignancies.  J Assoc Genet Tenchol. 2010;36(3):107-109.
11. Liu L, Nam S, Tian Y, et al. 6-Bromoindirubin-3'-oxime Inhibits JAK/
STAT3 signaling and induces apoptosis of human melanoma cells. 
Cancer Res. 2011;71(11):3972-3979.
12. Tam L, McGlynn LM, Traynor P, et al. Expression levels of the JAK/
STAT pathway in the transition from hormone-sensitive to hormone-
refractory prostate cancer. Br J Cancer. 2007;97(3):378-383.
13. O’Shea JJ, Schwartz DM, Villarino AV, et al. The JAK-STAT pathway: 
impact on human disease and therapeutic intervention. Annu Rev 
Med. 2015;66:311-28.
14. Kang K, Robinson GW, Hennighausen L. Comprehensive meta-analysis 
of Signal Transducers and Activators of Transcription (STAT) genomic. 
BMC Genomics. 2013;14:4.
15. Siersbaek R, Nielsen R, John S, et al. Extensive chromatin remodelling 
and establishment of transcription factor. EMBO J. 2011;30(8):1459-
1472.
16. Malin S, McManus S, Cobaleda C, et al. Role of STAT5 in controlling 
cell survival and mmunoglobulin gene recombination during pro-B 
cell development. Nat Immunol. 2010;11(2):171-9.
17. Liu M, Xiao CQ, Sun MW, et al. Xanthatin inhibits STAT3 and NF-κB 
signalling by covalently binding to JAK and IKK kinases. J Cell Mol 
Med. 2019;23(6):4301-4312.
18. Rumi E, Pietra D, Pascotto C, et al. Clinical effect of driver muta-
tions of JAK2, CALR, or MPL in primary myelofibrosis. Blood. 
2014;124(7):1062-1069.
19. Tefferi A,  Lasho TL, Finke CM, et al. CALR vs JAK2 VS MPL-mutated 
or triple-negative myelofibrosis: clinical, cytogenetic and molecular 
comparisons. Leukemia. 2014;28(7):1472-1477.
20. Papaemmanuil E, Gerstung M, Malcovati L, et al.; Chronic Myeloid 
Disorders Working Group of the international cancer genom con-
sortium. Clinical and biological implications of driver mutations in 
myelodysplastic syndromes. Blood. 2013;122(22):3616-3627. 
21. Berg JM, et al. Biochemistry. 5th ed. New York: W.H. Freeman; 2002. 
22. Niwa Y, Kanda H, Shikauchi Y, et al. Methylation silencing of SOCS-
3 promotes cell growth and migration by enhancing JAK/STAT and 
FAK signalings in human hepatocellular carcinoma. Oncogene. 
2005;24(42):6406-6417.
23. Meszaros EC, Malemud CJ. Phosphorylation of STAT proteins by 
recombinant human IL-6 in immortalized human chondrocyte cell 
lines, T/C28a2 and C28/I2. J Inflamm Res. 2017;10:143-150.
24. Yin, D. (2013). Functional graphene oxide as a plasmid-based Stat3 
siRNA carrier inhibits mouse malignant melanoma growth in vivo. 
Nanotechnology, 24(10), 1-12.
25. Yamamoto R, Nishikori M, Tashima M, et al. B7-H1 expression is 
regulated by MEK/ERK signaling pathway in anaplastic large cell 
lymphoma. Cancer Sci. 2009;100(11):2093-3000.
26. Vicente C, Schwab C, Broux M, et al. Targeted sequencing identi-
fies associations between IL7R-JAK mutations and epigenetic 
modulators in T-cell acute lymphoblastic leukemia. Haematologica. 
2015;100(10):1301-1310.
27. Della Porta MG, Malcovati L. Clinical relevance of extra-hematologic 
comorbidity in the management of patients with myelodysplastic 
syndrome. Haematologica. 2009;94(5):602-606.
28. Andrikovics H, Krahling T, Balassa K, et al. Distinct clinical charac-
teristics in myeloproliferative neoplasms with calreticulin mutations. 
Haematologica. 2014;99(7):1184-1190.
29. McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 family of cytokines in 
health and disease. Immunity. 2019;50(4):892-906.
30. Cazzola M, Della Porta MG, Malcovati L. The genetic basis of myelo-
dysplasia and its clinical relevance. Blood. 2013;122(25):4021-4034.
31. Rampal R, Al-Shahrour F, Abdel-Wahab O, et al. Integrated genomic 
analysis illustrates the central role of JAK-STAT pathway activation in 
myeloproliferative neolasm pathogenesis. Blood. 2013;123(22):e123-
133.
32. Vignali DA, Kuchroo VK. IL-12 family cytokines: immunological 
playmakers. Nat Immunol. 2012;13(8):722-728.
33. Gou, Y. (2012). Interleukin-6 signaling pathway in targeted therapy 
for cancer. Cancer treatment reviews, 38 (7 ), 904-910.
34. Nairismägi M, Gerritsen ME, Li ZM, et al. Oncogenic activation of 
JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel 
selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma. 
Leukemia. 2018;32(5):1147-1156.
35. Adamson AS, Collins K, Laurence A, et al. The current status of lym-
phocytes signaling: new roles for old players. Curr Opin Immunol. 
2009;21(2):161-166.
36. Delgoffe GM, Vignali DA. STAT heterodimers in immunity: a mixed 
message or a unique signal? JAKSTAT. 2013;2(1):e23060.
37. Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338 
patients with polycythemia vera: the impact of JAK2 (V617F) allele 
burden and leukocytosis on fibrotic or leukemic disease transforma-
tion and vascular complications. Leukemia. 2010;24(9):1575-1579.
38. Seif F, Khoshmirsafa M, Aazami H, et al. The role of JAK-STAT 
signaling pathway and its regulators in the fate of T helper cells. Cell 
Commun Signal. 2017;15(1):23.
51
